Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer

doi: 10.1016/j.jpha.2024.101001

• Xiang Ling^a,b , 
• Wenjie Wu^a,b , 
• Li Yan^c , 
• Leslie Curtin^d , 
• Melanie M. Farrauto^d , 
• Sandra Sexton^d , 
• Anmbreen Jamroze^a , 
• Changjun Yu^e , 
• Christos Fountzilas^f,g,h , 
• Dean G. Tang^a,g,i , 
• Fengzhi Li^{a,g,h,i ,  ,} 

• a Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, USA;

• b Canget BioTekpharma LLC, Buffalo, New York 14203, USA;

• c Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center Buffalo, New York 14263, USA;

• d Comparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, USA;

• e California Institute of Technology, Pasadena, California 91125, USA;

• f Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, USA;

• g Developmental Therapeutics (DT) Program, Roswell Park Comprehensive Cancer Center; Buffalo, New York 14263, USA;

• h Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center; Buffalo, New York 14263, USA;

• i Genitourinary (GU) Oncology Research Center, Roswell Park Comprehensive Cancer Center; Buffalo, New York 14263, USA